Active substanceHaloperidolHaloperidol
Similar drugsTo uncover
  • Haloperidol
    pills inwards 
    ALSI Pharma, ZAO     Russia
  • Haloperidol
    solution w / m 
  • Haloperidol
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Haloperidol
    pills inwards 
    BIOKOM, CJSC     Russia
  • Haloperidol
    pills inwards 
  • Haloperidol
    solution w / m in / in 
    Biocanol Farma GmbH     Germany
  • Haloperidol
    pills inwards 
    ORGANICS, JSC     Russia
  • Haloperidol
    solution w / m 
    BINNOFARM, CJSC     Russia
  • Haloperidol
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Haloperidol
    pills inwards 
    OZONE, LLC     Russia
  • Haloperidol decanoate
    solution inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Acry®
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
  • Haloperidol-ratopharm
    drops inwards 
    ratiofarm GmbH     Germany
  • Haloperidol-Richter
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Richter
    solution inwards w / m 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Richter
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Ferein
    solution w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Senorm
    solution w / m 
  • Senorm
    solution w / m in / in 
  • Dosage form: & nbsptabscesses
    Composition:

    One tablet contains:

    active substance: Haloperidol in terms of 100% substance - 1.5 mg and 5 mg;

    Excipients: lactose monohydrate, potato starch, silicon dioxide colloid (aerosil), talc, magnesium stearate.

    Description:

    Tablets from white to white with a yellowish or kremovatym shade of color, ploskotsilindricheskie, with a facet.

    Tablets with a dosage of 5 mg are at risk.

    Pharmacotherapeutic group:Antipsychotic agent (antipsychotic)
    ATX: & nbsp

    N.05.A.D.01   Haloperidol

    Pharmacodynamics:

    Antipsychotic agent (neuroleptic), a derivative of butyrophenone. Has a pronounced antipsychotic effect, blocks postsynaptic dopamine receptors in the mesolimbic and mesocortical structures of the brain. High antipsychotic activity is combined with a moderate sedative effect (in small doses has an activating effect) and pron protandthiefbothth action. Causes extrapyramidal disorders, virtually no cholinoblocking effect.

    Sedative action is due to blockade of alpha-adrenergic receptors of the reticular formation of the brain stem; antiemetic effect - blockade of dopamine D2receptors of the trigger zone of the vomiting center; hypothermic action and galactorrhea - blockade of dopamine receptors of the hypothalamus.

    Prolonged reception is accompanied by a change in the endocrine status, in the anterior pituitary gland prolactin production increases and decreases - gonadotropic hormones.

    Effective in patients resistant to other neuroleptic drugs. Has some activating effect.

    In hyperactive children, eliminates excessive motor activity, behavioral disorders (impulsivity, difficulty concentrating, aggressiveness).

    Pharmacokinetics:

    Absorption if taken orally - 60%. The maximum concentration in blood plasma for oral intake is achieved in 3 hours. The volume of distribution is 18 l / kg, the connection with plasma proteins is 92%. Easily passes through the histohematological barriers, including the blood-brain barrier.

    Metabolized in the liver, has the effect of "first pass" through the liver.In the metabolism of the drug, isozymes participate CYP2D6, CYP3A3, CYP3A5, CYP3A7. It is an inhibitor CYP2D6. There are no active metabolites. The elimination half-life is 24 h (12-37 h).

    It is excreted with bile and urine: with bile 15% are excreted, with urine - 40% (including 1% in unchanged form). Penetrates into breast milk.

    Indications:

    - Acute and chronic psychoses accompanied by excitement, hallucinatory and delusional disorders, manic conditions, psychosomatic disorders;

    - Behavioral disorders, personality changes (paranoid, schizoid and others), Gilles de la Tourette's syndrome, both in childhood and in adults;

    - Ticks, Guggington's chorea;

    - long-lasting and resistant to therapy vomiting, including associated with antitumor therapy, and hiccups.

    Contraindications:

    - Hypersensitivity, severe inhibition of central nervous system function against xenobiotic intoxication, coma of various genesis;

    - diseases of the central nervous system, accompanied by pyramidal or extrapyramidal symptoms (including Parkinson's disease);

    - Depression, hysteria;

    - galactose intolerance, lactase deficiency or glucose-galactose malabsorption;

    - pregnancy, lactation period;

    - Children's age (up to 3 years).

    Carefully:

    Decompensated diseases of the cardiovascular system (including angina pectoris, intracardiac conduction disorders, lengthening of the interval Q-T or a predisposition to this - hypokalemia, the simultaneous use of other drugs that can cause lengthening of the interval Q-T), epilepsy, zakratougolnaya glaucoma, hepatic and / or renal failure, hyperthyroidism (with thyrotoxicosis), pulmonary-cardiac and respiratory failure (including chronic obstructive pulmonary disease and acute infectious diseases), prostatic hyperplasia with a delay in urine , alcoholism.

    Dosing and Administration:

    Inside, for half an hour before a meal (you can with milk to reduce the irritant effect on the gastric mucosa).

    Initial dose for adults - 0.5-5 mg 2-3 times a day. If necessary, the dose is gradually increased by 0.5-2 mg until the desired therapeutic effect is achieved. The maximum dose is 100 mg / day.

    On average, the therapeutic dose is 10-15 mg per day, for chronic forms of schizophrenia - up to 20-40 mg, in resistant cases - up to 50-60 mg per day.

    The average duration of treatment is 2-3 months.

    Reduce the dose slowly, maintenance doses (outside the exacerbation) - from 0.5 to 5 mg per day.

    Elderly or weakened patients at the beginning of treatment are prescribed by mouth for 0.5-2 mg 2-3 times a day (1 / 3-1 / 2 of the usual dose for adults) with its increase not more often than every 2-3 days.

    Children 3-12 years old (with a body weight of 15-40 kg) - 0,025-0,05 mg / kg / day in 2-3 divided doses; if necessary taking into account the tolerability dose increase 1 time for 5-7 days to a total dose of 0.15 mg / kg / day.

    As an antiemetic, appoint inwards for 1.5-3 mg.

    If it is not possible to accurately dose in children and adults, it is recommended to take adequate dosage forms.

    Side effects:

    From the nervous system: headache, dizziness, insomnia or drowsiness (varying degrees of severity), anxiety, anxiety, psychomotor agitation, fear, akathisia, euphoria, depression, epileptic seizures; in rare cases - exacerbation of psychosis, including hallucinations; extrapyramidal disorders, with long-term treatment - tardive dyskinesia (smacking lips and lips, inflating cheeks, quick and wormlike movements of the tongue, uncontrolled chewing movements, uncontrolled movements of the hands and feet), late dystonia (rapid blinking or spasms of the eyelids, unusual facial expression or position of the body , uncontrolled bending movements of the neck,torso, arms and legs) and malignant neuroleptic syndrome (shortness of breath or shortness of breath, tachycardia, arrhythmia, hyperthermia, increased or decreased blood pressure, increased sweating, urinary incontinence, muscle rigidity, convulsive disorders, depression).

    From the cardiovascular system: when used in high doses - lowering blood pressure, orthostatic hypotension, arrhythmias, tachycardia, ECG changes (prolongation of the Q-T interval, signs of flutter and fibrillation of the ventricles).

    From the digestive system: when used in high doses - decreased appetite, dry mouth, hypo-salivation, nausea, vomiting, diarrhea or constipation, impaired liver function, until the development of jaundice.

    From the hematopoiesis: rarely - temporary leukopenia or leukocytosis, agranulocytosis, erythropenia and a tendency to monocytosis.

    From the genitourinary system: retention of urine (with hyperplasia of the prostate gland), peripheral edema, pain in the mammary glands, gynecomastia, hyperprolactinaemia, violation of the menstrual cycle, decreased potency, increased libido, priapism.

    From the sense organs: cataract, retinopathy, blurred vision.

    Allergic reactions: maculopapular and acne-like skin changes, photosensitivity; rarely - bronchospasm, laryngospasm.

    Laboratory indicators: hyponatremia, hyper- or hypoglycemia.

    Other: alopecia, weight gain.

    Overdose:

    Symptoms: depression of consciousness, rigidity of muscles, tremor, drowsiness, lowering of arterial pressure, sometimes - increase of arterial pressure. In severe cases - coma, respiratory depression, shock.

    Treatment: ingestion - gastric lavage, Activated carbon. With respiratory depression - artificial ventilation. To improve blood circulation in / in, inject plasma or albumin solution, norepinephrine. Epinephrine in these cases, use is strictly prohibited! Reduction of extrapyramidal symptoms - central holinoblokatory and antiparkinsonian drugs. Dialysis is ineffective.

    Interaction:

    Increases the severity of the inhibitory effect on the central nervous system of ethanol, tricyclic antidepressants, opioid analgesics, barbiturates and hypnotics, funds for general anesthesia.

    Strengthens the action of peripheral m-holinoblokatorov and most antihypertensives (reduces the effect of guanetidine due to its displacement from alpha-adrenergic neurons and suppression of its capture by these neurons).

    It inhibits the metabolism of tricyclic antidepressants and monoamine oxidase inhibitors (MAO), while their (mutually) sedative effect and toxicity increase.

    With simultaneous use with bupropion reduces the epileptic threshold and increases the risk of major epileptic seizures.

    Reduces the effect of anticonvulsants (reducing the convulsive threshold with haloperidol).

    , Decreases the vasoconstrictor action of dopamine, phenylephrine, norepinephrine, epinephrine and ephedrine (alpha adrenoceptor blockade haloperidol, which can lead to distortion of the action of epinephrine and a paradoxical decrease in blood pressure).

    Reduces the effect of antiparkinsonian agents (antagonistic effect on the dopaminergic structures of the central nervous system).

    Changes (may increase or decrease) the effect of anticoagulants.

    Reduces the effect of bromocriptine (dose adjustment may be required).

    When used with methyldopa increases the risk of developing mental disorders (including disorientation in space, slowing and hindering thinking processes).

    Amphetamines reduce antipsychotic effect of haloperidol, which, in turn, reduces their inducing effect (haloperidol blockade of alpha-adrenoceptors).

    Anticholinergic, antihistamine (1st generation) and antiparkinsonian drugs can enhance the m-halo-blocking effect of haloperidol and reduce its antipsychotic effect (dose adjustment may be required). Long-term administration of carbamazepine, barbiturates and other inducers of microsomal oxidation reduces the concentration of haloperidol in plasma.

    In combination with lithium preparations (especially in high doses), the development of encephalopathy (can cause irreversible neurointoxication) and an increase in extrapyramidal symptoms.

    With simultaneous administration with fluoxetine, the risk of side effects from the central nervous system increases, especially extrapyramidal reactions.

    With simultaneous use with drugs that cause extrapyramidal reactions, increases the frequency and severity of extrapyramidal disorders.

    The use of strong tea or coffee (especially in large quantities) reduces the effect of haloperidol.

    Special instructions:

    During therapy, patients should regularly monitor the ECG, the blood formula, and "liver" tests.

    With the development of tardive dyskinesia, it is recommended that the dose be gradually reduced (until the drug is completely discontinued).

    Care must be taken when performing heavy physical work, taking a hot bath (it is possible to develop a heat stroke due to the suppression of central and peripheral thermoregulation in the hypothalamus).

    During treatment, do not take "cold" non-prescription drugs (possibly increasing the anticholinergic effects and the risk of heat stroke).

    Protect open areas of the skin from excessive sunlight due to the increased risk of photosensitivity.

    Treatment is stopped gradually to avoid the occurrence of the "withdrawal" syndrome.

    An antiemetic effect can mask the signs of drug toxicity and make it difficult to diagnose conditions, the first symptom of which is nausea.

    It was noted that doses for children 6 mg / day cause additional improvement in behavioral disorders and tics.

    Effect on the ability to drive transp. cf. and fur:

    During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:

    Tablets, 1.5 mg and 5 mg.

    Packaging:

    For 10 tablets in a planar cell package,

    5 contour mesh packages together with instructions for use in a pack of cardboard.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002707 / 01
    Date of registration:22.05.2008
    Expiration Date:Unlimited
    Date of cancellation:2018-02-16
    The owner of the registration certificate:AKRIKHIN HFK, JSC AKRIKHIN HFK, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp18.02.2018
    Illustrated instructions
      Instructions
      Up